Last reviewed · How we verify

NCT06169605

Assessment of the Effect of Tumor Thickness and Site on Level IV Cervical Lymph Nodes in Squamous Cell Carcinoma of the Tongue and Floor of the Mouth: A Case Series Study

Recruiting now NA Last updated 29 May 2024
What this trial tests

NA trial testing removal of primary tumor, neck dissection in Tongue Neoplasms in 20 participants. Currently enrolling.

Timeline
1 April 2024
Primary endpoint
30 May 2025
30 May 2025

Quick facts

Lead sponsorCairo University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date1 April 2024
Primary completion30 May 2025
Estimated completion30 May 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Cairo University

Who can join

Adults 15 to 60, any sex, with Tongue Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Regarding oral cavity cancer, the high incidence of neck metastasis along with its impact on survival and prognosis are in favor of elective neck dissection. Moreover, occult metastases could develop at lower levels in the neck (levels IV-V) Regarding the tongue, the rate of skip (occult) metastasis involving unremoved level IV cervical lymph nodes in squamous cell carcinoma of the tongue ranges from 0 % - 11.4 %. However, no data is available or a correlation between the risk of level IV involvement and the affection of specific tongue subsites or a certain cutoff value of tumor thickness.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Cairo University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06169605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing